About Cullinan Oncology
Cullinan Oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. Sourced from the Cullinan dry lab as well as external collaborators, Cullinan’s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.
Co-Founder and CSO: Patrick Baeuerle, PhD
CEO: Owen Hughes
CSO: Leigh Zawel, PhD
Please click here for Cullinan Oncology's approach.
8 articles with Cullinan Oncology
The EMBL has presented Baeuerle with the 2019 Lennart Philipson Award for his pivotal role in developing cancer immunotherapies.
Taiho Pharmaceutical and Cullinan Oncology Establish Collaboration to Develop TAS6417, Novel EGFR Tyrosine Kinase Inhibitor
FIH Study in EGFR Exon 20 Insertions Will Commence in 2019
First-in-class small molecule targeting EBV-driven cancers to enter Phase 1 in 2019
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
Cullinan Oncology and MAB Discovery Announce Collaboration to Develop Novel Antibody-Based Therapeutics
Cullinan Oncology, LLC and MAB Discovery GmbH (MABD), announced today the initiation of a collaboration to develop novel antibody therapeutics based on MABD’s unique discovery platform.
The company announced today the appointment of Thomas Ebeling and Tony Rosenberg to its Board of Directors.
10/25/2017Rumor is there's a new approach to fighting cancer in town.